Genomic Health (GHDX) Tops Q4 EPS by 2c, FY15 EPS Misses Consensus

Genomic Health (NASDAQ: GHDX) reported Q4 EPS of ($0.20), $0.02 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $69.1 million versus the consensus estimate of $72.2 million.

Genomic Health sees FY2015 EPS of ($0.53)-($0.75), versus the consensus of ($0.52). Genomic Health sees FY2015 revenue of $292-305 million, versus the consensus of $310.61 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping withdraws bid to acquire Genco Shipping
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c